Answers are grounded in this paper and cite their sources.
Hypothyroidism often requires lifelong thyroid hormone replacement, but oral levothyroxine (LT4) treatment depends on daily administration and gastrointestinal absorption. Here, we developed an LT4-loaded barbed dissolving microneedle patch based on poly-γ-glutamic acid (γ-PGA) (LT4@MN) for reduced-frequency transdermal delivery. LT4 was incorporated into the needle region, while the γ-PGA backing was prepared without the drug. The microneedles exhibited well-defined morphology, sufficient mechanical strength, moisture-responsive dissolution behavior, effective skin penetration to a depth of approximately 700 μm, and favorable cytocompatibility. In a total thyroidectomy-induced hypothyroid rat model, LT4@MN administered once every 6 days increased serum total thyroxine (TT4) from the hypothyroid baseline and maintained elevated TT4 levels across three consecutive treatment cycles. However, serum thyroid-stimulating hormone (TSH) did not show a clear sustained decrease during treatment. Repeated application caused no obvious local tissue damage or histopathological abnormalities in major organs. These findings support the feasibility of reduced-frequency transdermal LT4 delivery using barbed dissolving γ-PGA microneedles and highlight their potential as a minimally invasive alternative to daily oral administration.
No takes yet. Share an insight, caveat, or question.
He et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: